Eli Lilly's weight management drug Zepbound outperforms Wegovy, with potential Amazon Pharmacy partnership boosting sales and making Lilly stock attractive.

Eli Lilly's Zepbound, a weight management drug, shows promising sales growth, outpacing Novo Nordisk's Wegovy. A partnership with Amazon Pharmacy may further boost sales. This collaboration could make Eli Lilly stock a smart buy, as the company's newest weight management treatment, tirzepatide (Mounjaro), has performed well in the diabetes treatment market.

March 17, 2024
3 Articles